2796 — Pharmarise Holdings Income Statement
0.000.00%
Last trade - 00:00
- ¥7bn
- ¥13bn
- ¥52bn
- 65
- 89
- 26
- 68
2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 51,728 | 51,030 | 52,324 | 51,608 | 52,030 |
Cost of Revenue | |||||
Gross Profit | 7,342 | 7,438 | 8,068 | 8,117 | 8,134 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 51,269 | 50,258 | 51,446 | 50,306 | 50,969 |
Operating Profit | 459 | 772 | 878 | 1,302 | 1,061 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 400 | 819 | 1,202 | 1,322 | 1,049 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10 | 581 | 420 | 458 | 347 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 23 | 578 | 426 | 448 | 333 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 23 | 579 | 428 | 449 | 335 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 73.8 | 111 | 110 | 104 | 97.6 |
Dividends per Share |